Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3848814 | 0.98 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL4458055 | 0.97 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3850110 | 0.97 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3854111 | 0.97 | ITGA4 (0.53) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL4415981 | 0.95 | ITGA4 (0.50) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL4431680 | 0.95 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3851145 | 0.95 | ITGA4 (0.54) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3853214 | 0.95 | ITGA4 (0.52) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3849319 | 0.95 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 | |
| SCHEMBL3849746 | 0.95 | ITGA4 (0.51) | ITGA4P2RX7CACNA1BITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | claimed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-7576101-B2 | Using sulfonamides such as N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine isopropyl ester optionally with immunoglobulins, steroids, antiinflammatory agents | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7320960-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-10-06 | — | — | US | disclosed |
| US-6900179-B2 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-05-31 | — | — | US | disclosed |
| US-6525026-B2 | Antiinflammatory agents; cardiovascular disorders; rheumatic diseases | ELAN PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017993-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGA4 8/4885P2RX7 4659/4885CACNA1B 383/4885 |
| US-20050222119-A1 | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, L1CAM | ITGA4 8/4885P2RX7 4659/4885CACNA1B 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.